Skip to main content

BioMedNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Gains Attention as ‘Men’s Fitness’ Highlights unbuzzd Trial Results

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

Quantum BioPharma (NASDAQ: QNTM) is gaining broader consumer exposure following a recent Men’s Fitness review of clinical trial results for unbuzzd, a supplement drink designed to support alcohol metabolism and mental alertness after drinking. The randomized, double-blind, placebo-controlled study involving 26 participants found significantly lower estimated blood alcohol concentrations at several time points, improved self-rated alertness and reduced headache severity compared with a placebo. Quantum retains a financial interest in the consumer product through a 7% royalty on sales until payments reach $250 million, followed by a 3% perpetual royalty, as well as an equity stake in the brand’s operator and rights to pharmaceutical and medical applications of the formulation. The company is also developing REKVRY, a formulation intended for potential use in hospital and emergency settings, while pursuing broader commercialization of unbuzzd through its consumer brand.

To view the full article, visit https://ibn.fm/9pMNK

About Quantum BioPharma Ltd.

Quantum is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid”), Quantum is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum invented UNBUZZD(TM) and spun out its OTC version to Unbuzzd Wellness Inc. (“Unbuzzd”) (formerly, Celly Nutrition Corp.), led by industry veterans. Quantum retains ownership of 19.48% (as of June 30, 2026) of Unbuzzd. The agreement also includes royalty payments of 7% of sales from Unbuzzd until payments to Quantum total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Quantum retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses.

For more information visit www.QuantumBioPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Recent Quotes

View More
Symbol Price Change (%)
AMZN  250.55
-6.82 (-2.65%)
AAPL  345.52
-3.69 (-1.06%)
AMD  437.27
-51.92 (-10.61%)
BAC  47.85
-0.72 (-1.48%)
GOOG  270.54
-0.48 (-0.18%)
META  569.71
-26.51 (-4.45%)
MSFT  490.32
-7.98 (-1.60%)
NVDA  136.16
-9.82 (-6.73%)
ORCL  103.10
-7.47 (-6.76%)
TSLA  351.66
-22.75 (-6.08%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.